Atossa Therapeutics Inc Dossier - Source-backed chat

Atossa Therapeutics Inc

ATOSNASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)1.13

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.95Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $19.5M

Enterprise Value −$6.6M

Shares Outstanding 8.8M diluted

Next Earnings Date13 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing (Z)-endoxifen for breast cancer and rare diseases. While (Z)-endoxifen has demonstrated strong estrogen receptor inhibition and promising Phase 2 neoadjuvant data, the company remains pre-revenue with a high cash burn rate. The recent 1-for-15 reverse stock split in February 2026 and a $4.5 million registered direct offering in June 2026 highlight ongoing capital needs. Substantial doubt exists regarding its ability to continue as a going concern, making the stock a high-risk, high-reward clinical play that warrants a Hold recommendation until key Phase 2 readouts and further funding are secured.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$18.67

High · most bullish analyst$24.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case involves clinical setbacks, such as safety concerns or insufficient efficacy in the EVANGELINE trial, or a failure to secure additional capital. Given the going concern warning, severe dilution or a lack of funding could halt clinical development entirely.

Base CaseCentral scenario

The base case assumes Atossa successfully completes enrollment for the EVANGELINE Phase 2 trial by mid-2026 and reports positive preliminary data later in the year. The company utilizes its ATM facility and modest capital from the June 2026 offering to maintain operations, though further dilutive financing will be required to advance into Phase 3 trials.

Bull CaseUpside scenario

Atossa's proprietary oral formulation of (Z)-endoxifen bypasses liver metabolism and stomach acid degradation, offering a highly potent and tolerable alternative to tamoxifen. By expanding into rare pediatric endocrine and neuromuscular diseases like McCune-Albright Syndrome (MAS) and Duchenne Muscular Dystrophy (DMD), Atossa has secured Rare Pediatric Disease designations that could qualify the company for highly valuable Priority Review Vouchers (PRVs) worth $100M-$205M upon FDA approval, providing a clear path to non-dilutive value creation alongside its core oncology pipeline.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

(Z)-endoxifen bypasses CYP2D6 liver metabolism, offering more consistent systemic exposure than tamoxifen.
Promising early efficacy signals in neoadjuvant breast cancer settings (EVANGELINE and I-SPY 2 trials).
FDA Orphan Drug and Rare Pediatric Disease designations in DMD and McCune-Albright Syndrome provide potential PRV eligibility.

Key Investment Risks

Pre-revenue clinical-stage operations with substantial doubt about the company's ability to continue as a going concern.
High cash burn rate driven by accelerating clinical trial activity and legal expenses.
Risk of significant shareholder dilution from future equity offerings and warrant exercises.

Thesis Invalidation Triggers

Failure of (Z)-endoxifen to meet primary endpoints in the EVANGELINE Phase 2 trial.
Inability to raise additional capital, leading to a suspension of clinical programs.
Regulatory rejection or major delays in defining the clinical pathway with the FDA.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.